TABLE OF CONTENTS I
LIST OF FIGURES XVIII
LIST OF CHARTS XX
EXECUTIVE SUMMARY 1
U.S. ORTHOPEDIC BIOMATERIALS MARKET OVERVIEW 1
COMPETITIVE ANALYSIS 4
MARKET TRENDS 6
MARKET DEVELOPMENTS 8
PROCEDURE NUMBERS 9
MARKETS INCLUDED 11
KEY REPORT UPDATES 13
VERSION HISTORY 13
RESEARCH METHODOLOGY 14
1.1 RESEARCH SCOPE 14
1.2 IDATA’S 9-STEP METHODOLOGY 14
Step 1: Project Initiation & Team Selection 14
Step 2: Prepare Data Systems and Perform Secondary Research 16
Step 3: Preparation for Interviews & Questionnaire Design 17
Step 4: Performing Primary Research 18
Step 5: Research Analysis: Establishing Baseline Estimates 20
Step 6: Market Forecast and Analysis 21
Step 7: Identify Strategic Opportunities 23
Step 8: Final Review and Market Release 24
Step 9: Customer Feedback and Market Monitoring 25
DISEASE OVERVIEW 26
2.1 BASIC ANATOMY 26
2.1.1 Osteology and Musculoskeletal System 26
2.2 DISEASE PATHOLOGY AND DISORDERS 28
2.2.1 General Diagnostic 28
2.2.2 Osteoporosis 29
2.2.3 Osteoarthritis 29
2.2.4 Indication for Bone Graft Procedure 30
2.2.5 Indication for Cartilage Repair 31
2.2.6 Degenerative Disc Disease 32
2.3 PATIENT DEMOGRAPHICS 34
2.3.1 General Statistics 34
PRODUCT ASSESSMENT 36
3.1 PRODUCT PORTFOLIOS 36
3.1.1 Cellular Allografts 37
3.2 CLINICAL TRIALS 41
3.2.1 Cellular Allografts 41
CELLULAR ALLOGRAFT MARKET 47
4.1 INTRODUCTION 47
4.1.1 Lineage 48
4.1.1.1 Human Embryonic Stem Cells (hESC) 48
4.1.1.2 Mesenchymal Stem Cells (MSC) 48
4.1.2 Other Therapeutic Applications 48
4.2 MARKET OVERVIEW 50
4.3 MARKET ANALYSIS AND FORECAST 53
4.3.1 Total Cellular Allograft Market 53
4.3.1.1 Cervical Spine Stem Cell Market 55
4.3.1.2 Lumbar Spine Stem Cell Market 57
4.4 DRIVERS AND LIMITERS 59
4.4.1 Market Drivers 59
4.4.2 Market Limiters 60
4.5 COMPETITIVE MARKET SHARE ANALYSIS 62
ABBREVIATIONS 66
APPENDIX II: COMPANY PRESS RELEASES 68

Chart 1 1: Orthopedic Biomaterials Market by Segment, U.S., 2013 – 2023 3
Chart 1 2: Orthopedic Biomaterials Market Overview, U.S., 2016 & 2023 3
Chart 4 1: Orthopedic Cellular Allograft Market by Segment, U.S., 2013 – 2023 51
Chart 4 2: Orthopedic Cellular Allograft Market Breakdown, U.S., 2016 52
Chart 4 3: Orthopedic Cellular Allograft Market Breakdown, U.S., 2023 52
Chart 4 4: Total Orthopedic Cellular Allograft Market, U.S., 2013 – 2023 54
Chart 4 5: Cervical Spine Stem Cell Market, U.S., 2013 – 2023 56
Chart 4 6: Lumbar Spine Stem Cell Market, U.S., 2013 – 2023 58
Chart 4 7: Leading Competitors, Orthopedic Stem Cell Market, U.S., 2016 65

Figure 1 1: Orthopedic Biomaterials Market Share Ranking by Segment, U.S., 2016 (1 of 2) 4
Figure 1 2: Orthopedic Biomaterials Market Share Ranking by Segment, U.S., 2016 (2 of 2) 4
Figure 1 3: Companies Researched in this Report, U.S., 2016 5
Figure 1 4: Factors Impacting the Orthopedic Biomaterials Market by Segment, U.S. (1 of 2) 6
Figure 1 5: Factors Impacting the Orthopedic Biomaterials Market by Segment, U.S. (2 of 2) 7
Figure 1 6: Recent Events in the Orthopedic Biomaterials Market, U.S., 2013 – 2016 8
Figure 1 7: Orthopedic Biomaterials Markets Covered, U.S., 2016 (1 of 2) 9
Figure 1 8: Orthopedic Biomaterials Markets Covered, U.S., 2016 (2 of 2) 10
Figure 1 9: Orthopedic Biomaterials Markets Covered, U.S., 2016(1 of 3) 11
Figure 3 1: Estimates of Funding for Stem Cell Research 39
Figure 3 2: Cellular Allograft Products by Company 40
Figure 3 3: Transplantation of Autologous Bone Marrow or Leukapheresis-Derived Stem Cells for Treatment of Spinal Cord Injury 41
Figure 3 4: Safety and Efficacy of Autologous Mesenchymal Stem Cells in Chronic Spinal Cord Injury 41
Figure 3 5: rhBMP-2 in Cervical Arthrodesis 41
Figure 3 6: Interbody Spacers With map3® Cellular Allogeneic Bone Graft in Anterior or Lateral Lumbar Interbody Fusion 42
Figure 3 7: BMAC & Allograft vs BMP-2 43
Figure 3 8: Human Autograft Mesenchymal Stem Cell Mediated Stabilization of The Degenerative Lumbar Spine 43
Figure 3 9: Regenerative Medicine of Articular Cartilage: Characterization and Comparison of Chondrogenic Potential and Immunomodulatory Adult Mesenchymal Stem Cells (ARTHROSTEM) 44
Figure 3 10: Autologous Mesenchymal Stem Cells Transplantation for Spinal Cord Injury- A Phase I Clinical Study 44
Figure 3 11: Mesenchymal Stem Cells in Knee Cartilage Injuries 45
Figure 3 12: A Clinical Study of Outcomes in Foot and Ankle Bone Grafting Using map3® Cellular Allogeneic Bone Graft 45
Figure 3 13: Treatment of Knee Osteoarthritis With Allogenic Mesenchymal Stem Cells (MSV_allo) 46
Figure 4 1: Orthopedic Cellular Allograft Market by Segment, U.S., 2013 – 2023 (US$M) 50
Figure 4 2: Total Orthopedic Cellular Allograft Market, U.S., 2013 – 2023 53
Figure 4 3: Cervical Spine Cellular Allograft Market, U.S., 2013 – 2023 55
Figure 4 4: Lumbar Spine Stem Cell Market, U.S., 2013 – 2023 57
Figure 4 5: Drivers and Limiters, Orthopedic Stem Cell Market, U.S., 2016 61
Figure 4 6: Leading Competitors, Cellular Allograft Market, U.S., 2016 64
Figure 6 1: Press Release Summary 68

Medtronic
Genzyme
DePuy Synthes
Anika Therapeutics
Ferring Pharmaceuticals
Stryker
NuVasive
Bioventus
Zimmer Biomet
Integra LifeSciences
RTI Surgical
Fidia Pharmaceuticals
MTF
Orthofix
Arthrex
AlloSource
Aastrom
Baxter
Harvest Technologies
Wright Medical
Bacterin International
Arteriocyte
Exactech
LifeNet Health
Biocomposites
Alphatec Spine
Celling Biosciences
Globus Medical
Nuo Therapeutics
K2M
*Not all companies are currently active in every segment or sub-report from this suite. For more details contact an iData Research Product Advisor.